UNSPSC 51331703: Remoxipride

This classification denotes a dopamine antagonist with the molecular formula C16H23BrN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0223RD59PE, chemically known as (-)-(s)-3-bromo-n-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamide but generally known as remoxipride, which bears US NIH Compound Identifier 54477. European Medicines Agency schedules Remoxipride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10275MIG.

UNSPSC 51331703 Remoxipride is a Commodity code that maps poorly to recent state and local procurement activity; the single sourced opportunity involves naloxone and drug deactivation systems rather than remoxipride specifically. Naloxone and related harm-reduction pharmaceuticals and equipment represent the actual scope of work posted under this code in state and local contracting. Issuing bodies soliciting under the code include county health departments and public health agencies supporting community health and overdose-response initiatives.

Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the response deadline was July 26, 2023, at 2:00 p.m. The contract carries a two-year initial term with an option for one-year renewal, includes a three-month probationary termination clause, and requires E-Verify compliance, drug-free workplace certification, and standard insurance coverage (workers' compensation, commercial general liability, professional liability). The procurement is potentially FEMA-funded and subjects vendors to compliance audits under the Clean Air Act and Federal Water Pollution Control Act. The source supports no other recent opportunities under this code and no geographic spread beyond Florida.